Latigo Biotherapeutics (NASDAQ:LTGO) Raised to Strong-Buy at Jefferies Financial Group

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

A number of other analysts have also recently commented on the stock. Leerink Partners initiated coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price target on the stock. Wall Street Zen raised Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th. The Goldman Sachs Group started coverage on Latigo Biotherapeutics in a research note on Tuesday. They issued a “buy” rating and a $73.00 price objective on the stock. Finally, Guggenheim assumed coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company has an average rating of “Strong Buy” and an average price target of $52.25.

Latigo Biotherapeutics Stock Performance

Latigo Biotherapeutics stock opened at $22.26 on Tuesday. Latigo Biotherapeutics has a 52-week low of $17.22 and a 52-week high of $25.93.

Insider Buying and Selling at Latigo Biotherapeutics

In related news, Director James B. Tananbaum bought 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.